Table of contents

Electronic pages

• 11.15 MS incidence rates vary threefold by health board in scotland, persistently (14 November, 2019)

  Patrick Kearns, Peter Connick, Martin Paton, Martin O’Neill, Jonathon O’Riordan, James McDonald, Shuna Colville, Alberto Ascherio, Niall MacDougall, Siddharthan Chandran
• 11.27 Late onset multiple sclerosis in north wales (14 November, 2019)

  Venkatraman Karthikeayan, Yvonne Copeland, Catriona Fearn, Daniel Whittam, Liene Elsone, Saif Huda, Anu Jacob
• 11.51 Stiff person and related syndromes: review of 21 patients and their response to treatment (14 November, 2019)

  Joseph Thompson, Girija Sadalage, Abid Karim, Saiju Jacob
• 12.15 Distinguishing neurosarcoidosis from multiple sclerosis based on cerebrospinal fluid analysis: a retrospective cohort study (14 November, 2019)

  Tarunya Arun, Laura Pattison, Jacqueline Palace
• 11.15 ABN survey 2016: geographic variations in service provision (14 November, 2019)

  Peter Fernandes, Cath Mummery
• 11.27 Understanding variability in UK acute neurology services: what works, and what doesn’t? (14 November, 2019)

  Jonathan Best, Salwa Kamourieh, Cath Mummery
• 11.39 Association of british neurologists sustainability special interest group (ABN sustainability SIG): formation, objectives and invitation (14 November, 2019)

  Ann Cheesman, Daniel Blackburn, Camille Carroll, Anna Cohen, Jan Coebergh, Dilraj Sokhi, Sui H Wong, John Woolmore
• 11.51 Introducing atraumatic needles to the neurology ambulatory day case unit – a quality improvement project (14 November, 2019)

  Daniel White, Will Scotton, Zohra Shah, Tagore Nakornchai, Tamsin Critchlow, James Mitchell, Alex Sinclair, John Woolmore
• 12.03 Acute neurology: a two week snapshot in a district general hospital (14 November, 2019)

  Meneka Kanagaratnam, Ajay Boodhoo, Bridget MacDonald, Arani Nitkunan
• 12.15 Variation in neurology training: experiences from sites across the UK (14 November, 2019)

  Samuel Shribman, Sian Alexander, Angelika Zarkali, Thomas T Warner, Anthony Pereira, Tom Hughes, Catherine J Mummery
• 14.45 Relationships between walking speed, cognition & brain pathologies: an imaging study of the 1946 birth cohort (14 November, 2019)

  Sarah M Buchanan, Thomas D Parker, Christopher A Lane, Ashvini Keshavan, Sarah E Keuss, Anette E Schrag, Nick C Fox, Marcus Richards, Jonathan M Schott
• 14.57 Expanding the phenotypic spectrum of PSP: Findings from the PROSPECT-UK study (14 November, 2019)

  Edwin Jabbari, John Woodside, Alyssa Costantini, Andrew Lees, Huw Morris, on behalf of the PROSPECT-UK consortium
• 15.09 Inherited peripheral neuropathies: analysis of PDXK gene identifies a new treatable disorder (14 November, 2019)

  Viorica Chelban, Matthew P Wilson, Jodi Warman Chardon, Jana Vandrovcova, M Natalia Zanetti, Eleni Zamba-Papanicolaou, Stephanie Efthymiou, Simon Pope, Maria R Conte, Giancarlo Abis, Yo-Tsen Liu, Eloise Tribollet, Nourelhoda A Haridy, Juan A Botía, Mina Ryten, Paschalis Nicolaou, Anna Minaidou, Kyproula Christodoulou, Kristin D Kernohan, Alison Eaton, Matthew Osmond, Yoko Ito, Pierre Bourque, James EC Jepson, Oscar Bello, Fion Bremner, Carla Cordivari, Mary M Reilly, Martha Foiani, Amanda Heslegrave, Henrik Zetterberg, Simon JR Heales, Nicholas W Wood, James E Rothman, Kym M Boycott, Philippa B Mills, Peter T Clayton, Henry Houlden, for the Care4Rare Canada Consortium and the SYNaPS Study Group
• 15.21 Next-generation sequencing in charcot-marie-tooth disease: opportunities and challenges (14 November, 2019)

  Menelaos Pipis, Alexander M Rossor, Carolynne M Doherty, Matilde Laura, Mary M Reilly
• 15.33 Phenotype-genotype characterisation of ‘long survivors’ with motor neurone disease in Scotland (14 November, 2019)

  Danielle Leighton, Judith Newton, David Parry, Shuna Colville, Robert Swingler, Mary Porteous, Tim Aitman, George Gorrie, Siddharthan Chandran, Suvankar Pal
• 15.45 Recessive pentanucleotide repeat expansion in RFC1 causes CANVAS and late-onset sensory ataxia (14 November, 2019)

  Andrea Cortese, Mary M Reilly, Henry Houlden
• 14.45 Maintenance of idebenone treatment results in continued improvement in LHON patients (14 November, 2019)

  Xavier Lloria, Magda Silva, Catherine Lawrence-, Guenther Rudolph, Felice Lob, Bettina von Livonius, Claudia Catarino, Thomas Klopstock
• 14.57 How much of anti-CGRP monoclonal antibody preventive therapy for migraine is contextual (Placebo) effect? (14 November, 2019)

  Raeburn B Forbes, Mark O McCarron
• 15.09 Examining the neurological consequences of new psychoactive substances -‘legal highs’ (14 November, 2019)

  Rebekah Jones, Charles Kelleher, Matthew Tanti, Jeremy Cosgrove, Melissa Maguire
• 15.33 AVXS-101 in presymptomatic spinal muscular atrophy (SMA) (14 November, 2019)

  Kevin A Strauss, Kathryn J Swoboda, Michelle A Farrar, Hugh J McMillan, Julie Parsons, Jena M Krueger, Susan T Iannaccone, Claudia A Chiriboga, Jennifer M Kwon, Kayoko Saito, Mariacristina Scoto, Imran Kausar, Meredith Schultz, Elaine Kernbauer, Marcia Farrow, Francis G Ogrinc, Sarah Kavanagh, Douglas E Feltner, Bryan E McGill, Sidney A Spector, James L’Italien, Douglas M Sproule, Francesco Muntoni
• 09.00 Saved by the skin of his teeth: a job well done! (14 November, 2019)

  Fatima Jaffer, Naomi Sibtain, Paul Holmes
• 09.12 Hu dunnit? Anti-Hu associated paraneoplastic longitudinally extensive transverse myelitis, secondary to small-cell lung cancer (14 November, 2019)

  Puja R Mehta, Naomi A Sibtain, Fiona Norwood, Peter A Brex
• 09.24 Phone a friend? (14 November, 2019)

  Thomas Minton, Geraint Fuller, Simon Rinaldi, Janev Fehmi, Rose Bosnell, Eleanor Barton
• 09.36 A tumultuous case of episodic apnoea (14 November, 2019)

  Bo Sun, Victor Mgbachi, Mark Woodhall, Zanna Voysey, Laura Azzopardi, Prabha Rajan, Stephen Wroe, Patrick Waters, M Isabel Leite, Sarosh Irani
• 09.48 Acute psychosis in a young woman (14 November, 2019)

  Nikos Gorgoraptis, Magda Kolanko, Christina Petridou, Sachin Patel, Victoria Singh-Curry, Nicholas Davies, Sarosh Irani, Christopher Carswell
• 10.00 An obvious, deceptive, case of immunosuppression (14 November, 2019)

  Guru Kumar, Istvan Bodi, Lorena Flores
• 11.30 Comparison of fixed high dose with variable low dose rituximab in neuromyelitis optica spectrum disorders (14 November, 2019)

  Patricia Kelly, Daniel Whittam, Samantha Linaker, Kerry Mutch, Venkatraman Karthikeayan, Saif Huda, Anu Jacob
• 11.42 The scottish epilepsy deaths study (SEDS): identifying avoidable epilepsy-related deaths (14 November, 2019)

  Gashirai K Mbizvo, Christian Schnier, Colin R Simpson, Richard FM Chin, Susan E Duncan
• 12.18 Neurology led, outpatient plasma exchange: the wessex experience (14 November, 2019)

  Rachel Jennings, Chinar Osman, Katie Hill, Joanna Kitley, Ashwin Pinto
• 12.30 Do anticholinergic drugs increase alzheimer’s pathology in parkinson’s patients? A retrospective post-mortem investigation (14 November, 2019)

  Alan King Lun Liu, Yau Mun Lim, Ronald KB Pearce, Steve M Gentleman
• 11.30 Mutations in the glycosyltransferase domain of GLT8D1 cause ALS (14 November, 2019)

  Johnathan Cooper-Knock, Tobias Moll, Tennore Ramesh, Lydia Castelli, Christopher Shaw, Ammar Al-Chalabi, Christopher McDermott, Guillaume Hautbergue, Pamela Shaw
• 11.48 The misdiagnosis of functional disorders as neurological disease (14 November, 2019)

  Dennis Walzl, Alan Carson, Jon Stone
• 11.54 Current challenges in the assessment and diagnosis of optic disc swelling and idiopathic intracranial hypertension (14 November, 2019)

  George Ransley, Vivek Vijay, Laura Grant, Anish Bahra
• 12.06 Gait symptoms correlate with cognitive problems in parkinson’s (14 November, 2019)

  BS Tilley, M Romozzi, CM Hession, T Shiwani, MH Goldfinger, SM Gentleman, R Nicholas
• 001 Risperidone induced seizures after cessation of clozapine (14 November, 2019)

  Muhammad-Kazim Kanani
• 002 Management of idiopathic intracranial hypertension: an audit of the 2018 ABN guidelines (14 November, 2019)

  Matthew McWilliam, Rebecca Broad, Oliver Cousins, Lorena Flores, Sreedharan Harikrishnan
• 003 Diagnostic workup in suspected viral encephalitis-a single centre audit (14 November, 2019)

  Faizan Aslam, Helee Patel, Pablo Garcia-Reitboeck
• 004 A triaging blood test for neurology? Serum neurofilament levels in a cohort of GP referrals (14 November, 2019)

  Josephine Robertson, Elizabeth Gray, Alexander Thompson, Emily Feneberg, Kevin Talbot, Martin Turner
• 005 Unusual cerebellar stroke mimic with ATP1A3 mutation (14 November, 2019)

  Fuhad Ahmed, Niall John James MacDougall
• 006 Quality improvement: management of myotonic dystrophy patients in tertiary care centres (14 November, 2019)

  Sola Odunsi, Mark Roberts, James Lilleker, Andrew Bentley, Tim Felton
• 007 Simple steps to prevent CSF sample errors in neurological emergencies (14 November, 2019)

  Melanie P Jensen, Stephen D Auger
• 011 An anatomical approach to the immobile tongue (14 November, 2019)

  S Rajagopal, K Samra, D Athauda, MC Porter, M Lau, W Stern, J Spillane, P Holmes, A Roy, R Howard
• 013 Spinal cord biopsy in neuromyelitis optica: a case report (14 November, 2019)

  David OC Corbin, John Gill, Geoff de Caires, Jacqueline William, Matthew Gregory Torre
• 015 Beware the spasm: tonic spasms as the sole presenting feature in neuro-inflammatory disorders (14 November, 2019)

  Matthew McWilliam, Jananee Sivagnanasundaram, Sreedharan Harikrishnan
• 016 Bing-neel syndrome presenting with headache and TIA-like symptoms (14 November, 2019)

  Laura Azzopardi, Gargi Banerjee, Arvind Chandratheva
• 017 When the (genetics) penny drops… (14 November, 2019)

  Fiona Sutton, Miriam Mattoscio, Elisabeth Rosser, Rajith de Silva
• 018 Lost in translation: documentation of on call neurology advice and the clinical impact of discrepancies (14 November, 2019)

  Ammad Mahmood, Amy Davidson, Krishna Dani
• 019 A rare cause of oculomotor nerve palsy (14 November, 2019)

  Andrew Jones, Toby Williams, Amit Herwadkar, David McKee, Chris Kobylecki
• 020 A fluey man – a reason for neurologists to remain vigilant (14 November, 2019)

  Neena Singh, Amy Gimson, Ruth Dobson
• 021 Fludarabine-induced subacute, often fatal leukoencephalopathy: a case series (14 November, 2019)

  Amine Awad, Jamie Solis, Lydia Albjerg, Julie Albert, Elizabeth Bartrum, Richard Childs, Avindra Nath, Omar I Khan
• 022 Bilateral tapia’s syndrome following complication from coronary angiography – a case report (14 November, 2019)

  Jiaqi Shi, Varduhi Cahill, Saiju Jacob
• 024 Electronic intervention to improve acute neurology referral system (14 November, 2019)

  Emma Routledge, Oliver Ziff, Paul Jarman, Chris Turner, Arvind Chandratheva
• 025 The safety of etriage to provide advice rather than face-to-face neurology appointment (14 November, 2019)

  Karina Bennett, Louis de Boisanger, Fiona Moreton, Richard Davenport, Jon Stone
• 026 The walton centre integrated neurology nurse service (14 November, 2019)

  Nicholas Fletcher, Lydia Vallance, Julie Riley, Andrew Nicolson, Martin Wilson
• 027 Promoting atraumatic needle usage for lumbar puncture in neurology: the power of the default (14 November, 2019)

  Christian Holland, Catherine Moore, Vanessa Tobert, James Allen, Thomas Moore, Kirsty Durley, Evan Edmond
• 029 Importance of face-to-face consultation in complex decision-making (14 November, 2019)

  Richard Nicholas, Alessandra Solari, David Wilkie
• 030 Automating clinical audit in neurology (14 November, 2019)

  R Middleton, A Lacey, WO Pickrell, B Fonferfko-Shadrach, O Pearson, M Marta, G McDonnell, SE Thompson, DV Ford, R Nicholas
• 031 Managing rituximab delivery in a neurosciences centre (14 November, 2019)

  R Dorsey, T Williams, V Singh-Curry, M Johnson, J Pritchard, P Muraro, R Nicholas
• 032 Clinical audit research and evaluation for motor neurone disease (CARE-MND): alignment with clinical care standards (14 November, 2019)

  Emily Beswick, Judith Newton, Suvankar Pal, Shuna Colville, Richard Davenport, Ian Morrison, Robert Swingler, George Gorrie, Antony Bateman, Siddharthan Chandran
• 033 Audit on the diagnostic pathway of patients with glioma mimics (14 November, 2019)

  Dorothy Joe, Jose Lavrador, Francesco Vergani, Richard Gullan, Ranjeev Bhangoo, Keyoumars Ashkan, Gerald Finnerty
• 035 RAID referral patterns in neurology in-patients (14 November, 2019)

  Stephanie Mei Ling See, Varduhi Cahill, Geoffrey Khan, Saiju Jacob
• 036 mHealth in traumatic brain injury: a systematic review of the app markets and the literature (14 November, 2019)

  Edward Christopher, Kareem Alsaffarini, Aimun Jamjoom
• 038 MACE: optimal cut-offs for dementia and MCI (14 November, 2019)

  AJ Larner
• 039 Functional cognitive disorders: prognosis (14 November, 2019)

  Kariem Elhadd, Viraj Bharambe, AJ Larner
• 040 AD8: Likelihood to diagnose or misdiagnose (14 November, 2019)

  B Ziso, AJ Larner
• 041 Psychosis: a rare manifestation of moyamoya disease in an adult (14 November, 2019)

  Srishti Gupta, Amit Jaiswal, Srishti Sarkar, Akram Hosseini
• 042 Hydrophilic polymer embolisation causing subacute dementia (14 November, 2019)

  Naheed Raza, Peter Fernandez, Fiona Moreton, Siddharthan Chandran
• 043 A specialist cognitive clinic for the deaf community (14 November, 2019)

  Matthew Harris, Darica Au, Katy Judd, Joanna Atkinson, Catherine Mummery
• 045 Food for thought: an unusual case of frontotemporal dementia (14 November, 2019)

  Ronan O’Malley, Charles Romanovsky, Annalena Venneri, Daniel Blackburn
• 047 An unusual cause of psychosis (14 November, 2019)

  Ahmed Mubarak Mohamed, Daniel Blackburn, Ahmed Iqbal, Suveera Prasad
• 049 Characterising behaviour in behavioural variant frontotemporal dementia and semantic dementia (14 November, 2019)

  Rosie Heartshorne, Matthew Jones, Christopher Kobylecki, Julie S Snowden, Jennifer C Thompson
• 050 Western blot analysis of KPNA4 and its relevance to nucleocytoplasmic transport dysfunction in ALS/FTD (14 November, 2019)

  Anna Zatorska, Daniel Solomon, Tibor Hortobagyi, Frank Hirth
• 051 Novel patient pre-screening model improves patient recruitment and reduces screen-failure rates for AD clinical trials (14 November, 2019)

  Lucianne Dobson, Miguel Rosa-Grilo, Catherine Mummery
• 053 Altered phobic responses in frontotemporal dementia (14 November, 2019)

  Daniel Jimenez, Rebecca L Bond, Harri Sivasathiaseelan, Lucy L Russell, Caroline Greaves, Katrina Moore, Ione Woollacott, Rachelle Shafei, Charles R Marshall, Jonathan D Rohrer, Jason D Warren
• 054 Dementia mortality in wales: a population-based e-cohort (14 November, 2019)

  Tim Wilkinson, Christian Schnier, Ashley Akbari, Chris Orton, Ronan Lyons, Cathie Sudlow
• 055 The digital doctor: a fully automated stratification and monitoring system for patients with memory complaints (14 November, 2019)

  Ronan O’Malley, Bahman Mirhedari, Kirsty Harkness, Markus Reuber, Annalena Venneri, Heidi Christensen, Daniel Blackburn
• 056 Exploring the feasibility of automating verbal fluency tasks for cognitive assessment: data collection and analysis (14 November, 2019)

  Ronan O’Malley, Eric Brook, Alice Lewis, Isobel Sonksen, Bahman Mirhedari, Annalena Venneri, Heidi Christensen, Daniel Blackburn
• 057 Proteomic analysis of TDP-43 pathology in frontotemporal dementia (14 November, 2019)

  Rachelle Shafei, Christina Toomey, Martha Foiani, Kevin Mills, Tammaryn Lashley, Jonathan Rohrer
• 060 Fulminant meningitis as a presenting feature of anti-NMDA receptor encephalitis (14 November, 2019)

  Maria Stavrou, Jing Ming Yeo, Alexander David Slater, Sarosh Irani, Peter Foley
• 061 Management of NMDA-receptor encephalitis on the neurological ICU (14 November, 2019)

  Rachel Brown, Jennifer Spillane, Michael Lunn, Jeremy Radcliffe, Michael Zandi, Dimitri Kullmann, Robin Howard
• 062 Diagnostic investigations in suspected autoimmune and paraneoplastic encephalitis: a six-month retrospective audit (14 November, 2019)

  Michael Gilligan, Eleanor Wallace, Justin Kinsella
• 063 ‘Less contented as a person’: an update from the LGI1-QoL study (14 November, 2019)

  Sophie Binks, Michele Veldsman, Saiju Jacob, Paul Maddison, Jan Coebergh, M Isabel Leite, Masud Husain, Sarosh R Irani
• 064 Seizure patterns and trajectory in patients with epilepsy secondary to NMDA vs LGI1 auto-immune encephalitis (14 November, 2019)

  Arshia Seddigh, Omar Ezzat Mostafa, Abid Karim, Barbara Wysota, Shanika Samarasekera, Saiju Jacob
• 065 CXCL13 levels and autoantibody epitope specificities in LGI1-autoantibody syndromes (14 November, 2019)

  Sophia Michael, Melanie Ramberger, Isabel Maria Leite, Arjune Sen, Patrick Waters, Sarosh Irani
• 067 Bannwarth syndrome presentation of neuroborreliosis, with radiological evidence of CNS demyelination (14 November, 2019)

  Tim Soane, Fahad Shaikh, Grant Mair, Amy Baggott, Suvankar Pal
• 069 Progressive multifocal leukoencephalopathy in good’s syndrome (14 November, 2019)

  M Edwards, R Cousins, R Smith, NP Hinds
• 075 Meningitis management audit at a single centre: further support for culture-independent techniques in diagnosing meningitis (14 November, 2019)

  Simon Williams, Ghaniah Hassan-Smith
• 079 Genetic testing in epilepsy: a new imperative for precision (14 November, 2019)

  Nicholas Scott, Leigh Hamilton, Joe Symonds, Craig Heath, Hina Abbasi, Danielle Goldberg, Russell Hewitt, Victoria Marshall, Sameer Zuberi, John Paul Leach
• 080 A quality improvement project on the management of convulsive status epilepticus at ICHT (14 November, 2019)

  Charles Wade, Matthew Evans, Martin Osugo, Taryn Quinn, Rachel Dorsey, Alex Everett, John O’Dwyer, Mike Johnson, Nikos Gorgoraptis
• 082 Safety of ondansetron in a case series of patients with a predisposition to seizures (14 November, 2019)

  Laura White, Michelle Pipe, Tom Hayton, Nicholas Barnes
• 083 Facial twitching, breathlessness and fever: an unexpected and potentially lethal triad (14 November, 2019)

  Gashirai K Mbizvo, Isabel Lentell, Clifford Leen, Huw Roddie, Chris Derry, Susan Duncan, Kristiina Rannikmäe
• 084 A rare case of neurosyphilis imitating limbic encephalitis (14 November, 2019)

  Thomas Minton, Christina Giavasi, Donia Gamoudi
• 088 The walton seizure pathway – experience to date and outcomes (14 November, 2019)

  Nicholas Fletcher, Anthony Marson, Julie Riley, Martin Wilson, Andrew Nicolson
• 090 Anti-epileptic medications: causes of adherence failure (14 November, 2019)

  Mark Thaller, Maxine Maxwell, Carl-Christian Moor
• 091 Six years of perampanel: impact on patients with refractory epilepsy (14 November, 2019)

  Ann Dougan
• 092 The rare case of praxis and thinking reflex epilepsy (14 November, 2019)

  Alexandra Zirra, Nor Amelia Mohd Fauzi, Meneka Sidhu
• 094 The adult phenotypes of paediatric-onset genetic epilepsies (14 November, 2019)

  David Lewis-Smith, Donald Craig, Rhys Thomas
• 096 Perampanel: real life experience in swansea (14 November, 2019)

  Mouhamad Hussein Ismail, Robert Powell
• 098 The adult profile of SUDEP using the epilepsy deaths register (14 November, 2019)

  Donald Craig, Jane Hanna, Karen Osland, Mike Kerr, Rhys H Thomas
• 099 A retrospective study of mortality rates in a video-EEG telemetry patient cohort (14 November, 2019)

  Farhat Mirza, Varduhi Cahill, Paul Cooper, Rajiv Mohanraj
• 100 Progressive MRI and EEG changes in a patient with Creutzfeldt-Jakob disease (14 November, 2019)

  Naomi Johnson, Myat Thura, Shwe Tun, Walied Mowafi
• 101 PET-CT in patients with suspected paraneoplastic neurological conditions (14 November, 2019)

  Sanjay Cheema, John Young, Deborah Pencharz
• 102 Episodic memory functional connectivity in temporal lobe epilepsy (14 November, 2019)

  Sarah Buck, Lorenzo Caciagli, Sjoerd Vos, John S Duncan, Meneka Kaur Sidhu
• 104 Utility and incidental findings on CT chest, abdomen and pelvis scans in neurology patients (14 November, 2019)

  Ian Monaghan, Peter Fernandes
• 105 Ring-enhancing lesions – diagnostic challenge in a DGH (14 November, 2019)

  Aung Oo
• 107 Secondary intracranial hypertension in nephropathic cystinosis (14 November, 2019)

  Chloe Harijanto, Emily Pegg, Sumito Biswas, Tim Lavin
• 108 Audit of the management of idiopathic intracranial hypertension in the context of new consensus guidelines (14 November, 2019)

  Jessica Katanga, Arani Nitkunan
• 109 The walton headache pathway – design and outcome (14 November, 2019)

  Nicholas Fletcher, Anita Krishnan, Nicholas Silver, Julie Riley, Martin Wilson, Andrew Nicolson
• 110 Phenotype of new daily persistent headache (14 November, 2019)

  Rhannon Lobo, Sean Lobo, Benjamin Jacobs, Anish Bahra
• 111 An audit of headache referrals from primary care, and subsequent management in the outpatient clinic (14 November, 2019)

  Linford Fernandes, Matthew Tanti, Marc Randall, Jeremy Cosgrove
• 112 Spontaneous intracranial hypotension presenting as postural head tremor and gait ataxia (14 November, 2019)

  Priyadarshini Bangalore, Changez Jadun, Brenden Davies, Roby Abraham
• 113 Incidence of migraine and treatment patterns in UK primary care (14 November, 2019)

  Eleanor Yelland, Rebecca Ghosh, Tarita Murray-Thomas, Alison Williams, Victoria Hacking
• 115 Economic burden among migraine patients: United Kingdom perspective (14 November, 2019)

  Paolo Martelletti, Todd Schwedt, Michel Lanteri-Minet, Hans-Christoph Diener, Elena Ruiz de la Torre, Audrey Craven, Simon Evans, Donna Walsh, Paula Dumas, Annik Laflamme
• 119 Double jeopardy or VOMIT syndrome in trigeminal autonomic cephalalgias (14 November, 2019)

  Mark Thaller, MB Davies
• 121 Viral & bacterial RNA transcripts of substantia nigra and olfactory bulb in parkinson disease (14 November, 2019)

  Steve Kaye, James Abbott, Steve Gentleman, Wolfgang Oertel, Myra McClure, Christopher H Hawkes
• 122 Apomorphine infusion-induced ulcers and skin necrosis (14 November, 2019)

  Yann Shern Keh, Omesh Kulkarni
• 123 T and B lymphocyte senescence in parkinson’s disease (14 November, 2019)

  Melanie Jensen, Kirsten Scott, Marta Camacho, Julia Greenland, Antonina Kouli, Ruwani Wijeyekoon, Imtiaz Solim, Roger Barker, Caroline Williams-Gray
• 124 Real world use of neurophysiology in differentiating hyperkinetic movement disorders (14 November, 2019)

  Sacha E Gandhi, Monty A Silverdale, Deborah Mercer, Andrew G Marshall, Christopher Kobylecki
• 125 A case of multiple paraneoplastic syndromes associated with CRMP5 antibodies and lung cancer (14 November, 2019)

  Ahmad Alareed, Rebecca Broad, Oliver Cousins, Deepthi Changaradil, Ian Redmond, Lorena Flores Caimanque
• 126 Quality of life in idiopathic dystonia: a systematic review (14 November, 2019)

  Ayesha Girach, Ana Vinagre Aragon, Panagiotis Zis
• 127 Audit of poor response to botulinum toxin in cervical dystonia (14 November, 2019)

  Harry Tucker, Foster Osei-Poku, Diane Ashton, Rachael Lally, Jane Alty, Christopher Kobylecki
• 128 Efficacy and safety of deep brain stimulation in Parkinson’s disease: systematic review and meta-analysis (14 November, 2019)

  Sosipatros Bratsos, Dimitrios Karponis, Sohag Saleh
• 129 Validating a new dependency measurement for parkinson’s disease (14 November, 2019)

  Neil Ramsay, Angus Macleod, Carl Counsell
• 130 Trust the patient not the doctor: non-motor symptoms and quality of life in cervical dystonia (14 November, 2019)

  Ihedinachi Ndukwe, Sean O’Riordan, Michael Hutchinson
• 132 Does the use of a patient passport improve patient care in MND? A qualitative study (14 November, 2019)

  Reem Abdelgalil, Akshay Gaur, Channa Hewamadduma
• 133 Acute parkinsonism (14 November, 2019)

  Sacha E Gandhi, Vicky Marshall
• 135 Hyperhidrosis as an identifier in parkinson’s disease subtyping (14 November, 2019)

  Daniel van Wamelen, Valentina Leta, Aleksandra Podlewska, Yi-Min Wan, Katarina Krbot, Elina Jaakkola, Alexandra Rizos, Miriam Parry, Vinod Metta, K Ray Chaudhuri
• 136 Mitochondrial biomarkers in parkinson’s disease (14 November, 2019)

  Ryan L Davis, Siew L Wong, Phillipa J Carling, Thomas Payne, Carolyn M Sue, Oliver Bandmann
• 137 Usability testing of a non-motor symptom app in PD (14 November, 2019)

  Thea Dominey, Stephen Mullin, Emma Edwards, John Whipps, Sue Whipps, Camille Carroll
• 138 Clinical spectrum of AIFM1-associated phenotype in an irish family

  (14 November, 2019)

  Petya Bogdanova-Mihaylova, Michael D Alexander, Raymond P Murphy, Hongying Chen, Richard A Walsh, Sinéad M Murphy
• 139 Risk of parkinson’s in idiopathic anosmia (14 November, 2019)

  Richard N Rees, Carl Philpott, Simon Gane, Paul Worth, Alastair J Noyce, Anette Schrag
• 140 Defining clinical and genetic biomarkers in MSA (14 November, 2019)

  Viorica Chelban, John Woodside, Edwin Jabbari, Ruth Lamb, Martina Bocchetta, Jonathan Rohrer, Huw Morris, Henry Houlden
• 141 Switching from double-blind entacapone or placebo to open-label opicapone: NMSS results (1-year extension BIPARK-I study) (14 November, 2019)

  O Fabregues, E Tolosa, J Ferreira, A Lees, A Santos, J Rocha, P Soares-Da-Silva
• 142 Influence of baseline OFF-time on opicapone efficacy in Parkinson’s disease patients with motor fluctuations (14 November, 2019)

  P Korlipara, J Ferreira, H Gama, A Santos, F Ikedo, J Rocha, P Soares-Da-Silva
• 143 Dopamine transporter SPECT imaging: service evaluation from a tertiary neurosciences centre (14 November, 2019)

  Christopher Kobylecki, Jonathan Harris, Mark Boyle, Sandra Hoffmann
• 144 Studying corticobasal syndrome across the UK via the BNSU (14 November, 2019)

  Alyssa Costantini, Edwin Jabbari, Ruth Lamb, Marcia Darvell, John Woodside, Jon Rohrer, Andrew Lees, Huw Morris, on behalf of PROSPECT-UK & European CBS consortia
• 145 Pre-motor phase in autopsy-confirmed multiple system atrophy (14 November, 2019)

  Ekawat Vichayanrat, Eduardo De Pablo-Fernandez, Fernanda Valerio, Christopher Mathias, Jalesh Panicker, Janice Holton, Thomas Warner, Niall Quinn, Valeria Iodice
• 148 Longitudinal resting state changes in parkinson’s disease (14 November, 2019)

  Saadnah Naidu, Lily Yue Xing, Ali-Reza Mohammadi-Nejad, Stamatios Sotiropoulos, Dorothee Auer
• 149 Optical coherence tomography in an irish SPG7 cohort

  (14 November, 2019)

  Petya Bogdanova-Mihaylova, Hongying Chen, Helena Plapp, Sinéad M Murphy, Richard A Walsh
• 151 Improving diagnosis and care in progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) (14 November, 2019)

  Diane Swallow, Donald Grosset, Carl Counsell
• 153 The PHQ-9 as a tool to measure depression in people with multiple sclerosis (14 November, 2019)

  Suzanne Quigley, Emily Beswick, Pamela Macdonald, Peter Connick
• 155 Patient support program for RRMS patients treated with DMF (14 November, 2019)

  Joana Monterroso, Janette Curlis, Leontia Gribben
• 156 Some mainland Scottish localities have higher incidence rates than orkney (14 November, 2019)

  Patrick Kearns, Peter Connick, James MacDonald, Jonathon O’Riordan, Niall MacDougall, Shuna Colville, Martin Paton, Martin O’Neill, Alberto Ascherio, Siddharthan Chandran
• 157 Educational attainment of children born to mothers with MS (14 November, 2019)

  W Owen Pickrell, Arron S Lacey, Katharine Harding, Rod Middleton, Emma C Tallantyre, Gillian Ingram, Owen R Pearson, Mark I Rees, Neil P Robertson
• 158 CSF T-cell counts in multiple sclerosis diagnosis and prognosis (14 November, 2019)

  James Hrastelj, Mark Willis, Mark Bishop, Sam Loveless, Emma Tallantyre, Neil Robertson
• 159 Delayed-release dimethyl fumarate–associated lymphopenia (14 November, 2019)

  Andrew Chan, Robert J Fox, Amit Bar-Or, Chongshu Chen, Sami Fam, Ralf Gold, Jerome Hanna, Devangi Mehta, J Theodore Phillips
• 160 Ten-year clinical outcomes post treatment with mitoxantrone for relapsing remitting MS (14 November, 2019)

  Eng Chuan Foo, Melanie Russell, Oliver Lily, Helen Ford
• 161 Qualitative aspects of cognition in MS & audit of MoCA in LTHTR natalizumab cohort (14 November, 2019)

  Claire Gall
• 162 Doughnuts to sweet diagnosis (14 November, 2019)

  Vivien Li, Gordon Ingle
• 163 Development of clinical and patient-reported quality metrics for multiple sclerosis: a UK pilot study report (14 November, 2019)

  Gavin Giovannoni, Sarah White, Niraj Mistry, Samantha Calhoun, Carolyn Young, Mhairi Coutts, Megan Roberts, Philip Anderson, Rachel Bernstein, Jeremy Hobart
• 164 UK/ireland interim results from a DMF pregnancy registry (14 November, 2019)

  David Rog, Nicola Seferta, Christopher McGuigan, Nicholas Everage, Cynthia Jones
• 171 Alemtuzumab induced neutropaenia: women at risk (14 November, 2019)

  Riffat Tanveer, Adrian Pace, David Rog, Sharaf Nazar, Paul Talbot, Fran Jackson, Tatiana Mihalova
• 173 Outcome in a highly active multiple sclerosis cohort in the UK (14 November, 2019)

  Sabrina Kalam, Joe Hill, Ari Baheerathan, Miriam Mattascio, Rehiana Ali, Richard Nicholas, Paolo Muraro
• 174 Sclerosing dermopathy after alemtuzumab for multiple sclerosis (14 November, 2019)

  Damianou Marastoni, Joey Lai-Cheong, Roberta Magliozzi, Massimiliano Calabrese, Richard Nicholas
• 175 A model for participant engagement in research: the MS register (14 November, 2019)

  R Middleton, K Allen-Philbey, K Schmierer, M Espasandin, C Roberts, R Nicholas, J Rodgers, H Lockhart-Jones, K Tuite-Dalton, DV Ford
• 176 Fingolimod associated immune haemolytic anaemia (14 November, 2019)

  Omar AlMasri, Jeremy Hobart
• 177 Updated safety analysis of ocrelizumab in multiple sclerosis (14 November, 2019)

  Carolyn Young, Stephen Hauser, Ludwig Kappos, Xavier Montalban, Richard Hughes, Harold Koendgen, John McNamara, Ashish Pradhan, David Wormser, Jerry Wolinsky
• 178 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis (14 November, 2019)

  Gavin Giovannoni, Stephen L Hauser, Bruno Brochet, Xavier Montalban, Robert T Naismith, Jerry S Wolinsky, Stanislas Hubeaux, Lahar Mehta, Fabian Model, Ludwig Kappos
• 179 Early real-world experience of ocrelizumab in MS (14 November, 2019)

  Katharine Harding, Gillian Ingram, Emma Horton, Helen Owen, Fady Joseph, Owen Pearson
• 180 Cognitive diagnostic criteria lead to distinct patterns of functional connectivity in secondary progressive MS (14 November, 2019)

  Anisha Doshi, Gloria Castellazzi, Nils Muhlert, Adnan Alahmadi, Ferran Prados, Claudia Wheeler-Kingshott, Olga Ciccarelli, Jeremy Chataway
• 181 Multiple Sclerosis associated with Psoriasis – is alemtuzumab the drug of choice? (14 November, 2019)

  Venkatraman Karthikeayan, Daniel Whittam, Yvonne Copeland, Saif Huda, Anu Jacob
• 186 Familial multiple sclerosis: a community based epidemiological study in cumbria (14 November, 2019)

  May Nwe, David Footitt
• 191 MOBILE/ENHANCE integrated efficacy analysis of PR-fampridine (14 November, 2019)

  Raymond Hupperts, Jeremy Hobart, Claudio Gasperini, Jan Lycke, Tjalf Ziemssen, Peter Feys, Manjit McNeill, Carlos Acosta
• 192 Does socioeconomic status impact on the prescription of disease-modifying treatments in people with multiple sclerosis? (14 November, 2019)

  Saúl Reyes, Kimberley Allen-Philbey, Sebastian Suarez, Özlem Yildiz, Ben Turner, Sharmilee Gnanapavan, Klaus Schmierer, Monica Marta, Joela Mathews, Gavin Giovannoni
• 194 Natalizumab treatment for MS: UK and global results from TOP (14 November, 2019)

  Richard Nicholas, Timothy Harrower, Xiaoyu Jiang, Stephanie Licata, Jean Vonsy
• 195 MS disease modifying therapy (DMT) sequencing – tysabri to mavenclad de-escalation in JC-virus positive MS patients (14 November, 2019)

  Tatiana Mihalova, Karen Vernon, Nazar Sharaf, Paul Talbot, David Rog
• 198 A population study of temporal changes in MS disease modifying drug management and cost (14 November, 2019)

  Mark McCarron, Fiona Mullan, Carol Hinchcliff, Ferghal McVerry
• 199 Changes in natalizumab exposure and PML incidence over time (14 November, 2019)

  Gavin Giovannoni, Ludwig Kappos, Joseph Berger, Gary Cutter, Robert Fox, Heinz Wiendl, Ih Chang, Rachna Kasliwal, Lily Lee
• 200 AFFINITY: opicinumab in a targeted population of MS patients (14 November, 2019)

  Bing Zhu, Peter A Calabresi, Gavin Giovanonni, Raj Kapoor, Robert Naismith, Hans-Peter Hartung, Douglas L Arnold, Paul Wolstencroft, Kristina Johnson
• 201 Alemtuzumab related HPV infection and cervical dysplasia: real world data (14 November, 2019)

  Giles Ruffer, Anna Koniotes, Catherine Warren, Marco Bozzali, Leonora Fisniku
• 203 Infectious-like presentation of neuromyelitis optica with pyrexia and CSF lymphocytosis (14 November, 2019)

  Sanjay Cheema, Sara Leddy, Mirdhu Wickremaratchi
• 204 Therapeutic plasma exchange for neurological disorders: the experience of a tertiary neuroscience centre (14 November, 2019)

  Sarah Parker, Joyutpal Das, Channa Hewamadduma
• 205 An unusual cause of rapid cognitive decline in multiple sclerosis patient on natalizumab (14 November, 2019)

  Amar Elsaddig, Saifuddin Shaik
• 206 Follow your nose to the diagnosis (14 November, 2019)

  Vivien Li, Vinojini Vivekanandam, Michael Lunn
• 207 An atypical cause of longitudinally extensive transverse myelitis after an allogeneic haemopoietic stem cell transplant (14 November, 2019)

  Michael Kemp, Yann Shern Keh, Rejith Dayanandan, Muhammad Saif, John Nixon
• 208 Immune checkpoint inhibitor-related neurotoxicity: a case series (14 November, 2019)

  Rachel Brown, Lewis Au, Lavinia Spain, Andrew Furness, Jeremy Rees, Alex Rossor, Emma Morris, Michael Zandi, Michael Lunn, James Larkin, Samra Turajlic, on behalf of EXACT consortium, Aisling Carr
• 209 ‘How rare do we dare’ – hickam’s dictum taken to the extreme (14 November, 2019)

  EE Bunting, MP Lunn
• 210 CASPR2 antibody-related movement disorders: case series (14 November, 2019)

  Mei See, Varduhi Cahill, Sangeeta Scotton, Piers Newman, Girija Sadalage, Ajith Cherian, KP Divya, Saiju Jacob
• 212 Is there an ethnicity bias of access to MS services? The barts health experience revisited (14 November, 2019)

  Kimberley Allen-Philbey, Facundo Silveira, Ben Turner, Gavin Giovannoni, Klaus Schmierer
• 213 ‘Taking the brakes off’- immune checkpoint inhibitor induced neurotoxicity (14 November, 2019)

  Marie-Claire Porter, Sophie Papa, Paul Carroll, Victoria Williams
• 214 Analysis of CSF IgG index, IgG synthesis and clinical presentation among CSF OCBs negative patients (14 November, 2019)

  Tatiana Mihalova, Jing Ling Kwong, Hannah Alachkar
• 215 Demographic, clinical and paraclinical features in a subgroup of patients with NMOSD (14 November, 2019)

  Thomas Wegehaupt, Sriram Vundavalli, Sarah Cooper, Maria Leite, Jacqueline Palace, Leonora Fisniku
• 216 Retinitis pigmentosa and autoimmunity (14 November, 2019)

  Tatiana Mihalova, Kishan Pankhania, David McKee
• 218 Management strategies for neuroimmunological complications following treatment with immune checkpoint inhibitors (14 November, 2019)

  Smriti Bose, Salini Sumangala, Neil Steven, Saiju Jacob
• 219 First year of the early access to medicines scheme for raxone in duchenne muscular dystrophy (14 November, 2019)

  Catherine Lawrence, Shabir Hasham
• 221 Quality improvement project: updating the muscle biopsy referral form (14 November, 2019)

  Pamela Sarkar, Giles Atton, Kathryn Urankar, Nicola Long, Jennifer Patel, Joanne Smart, Stefen Brady
• 222 Investigating directionality of neurodegeneration in vivo in ALS using multimodal MRI (14 November, 2019)

  Charmaine L Toh, Andrew Keslake, Joseph Harding, Kathleen Baster, Nigel Hoggard, Julia Bigley, Christopher J McDermott, Pamela J Shaw, Iain D Wilkinson, Thomas M Jenkins
• 223 Anderson tawil syndrome: expanding the phenotype and assessing cardiac risk (14 November, 2019)

  Vinojini Vivekanandam, Konstantinos Savvitis, Jatin Pattni, Doreen Fialho, Michael G Hanna, Emma Matthews
• 224 Calpainopathy: CAPN compound heterozygosity in a patient with wilson’s disease (14 November, 2019)

  Charis Wong, Elaine Fletcher, Chiara Marini-Bettolo, Rita Barresi, David P Breen
• 225 Sporadic inclusion body myositis: a longitudinal observational study investigating outcome measures for clinical trials (14 November, 2019)

  Gina Sangha, Iwona Skorupinska, L Germain, A Bellin, Matthew Parton, Michael Hanna, James Miller, David Hilton-Jones, Jane Freebody, Pedro Machado
• 226 Quantitative strength profiling in inclusion body myositis (14 November, 2019)

  James B Lilleker, Alexander Oldroyd, Hector Chinoy, James AL Miller
• 227 An audit of adherence to ABN guidelines in myasthenia gravis diagnosis and management (14 November, 2019)

  Christopher Hutchcroft, Marc Boix-Codony, Shahd Hamid
• 229 Dysregulated axonal homeostasis in C9orf72 iPSC-derived motor neurones (14 November, 2019)

  Arpan Mehta, Bhuvaneish Selvaraj, Owen Dando, Karen Burr, Giles Hardingham, Siddharthan Chandran
• 230 A dog with a bone (marrow biopsy) (14 November, 2019)

  Vivien Li, Mahima Kapoor, Michael Lunn, Kate Cwynarski, Aisling Carr
• 235 Epidemiology of motor neurone disease in wales (14 November, 2019)

  Toni Saad, Ken Dawson, Claire Hirst, Idris Baker, Andrea Lowman, Mark Wardle, Katharine Harding, on behalf of the South Wales Motor Neurone Disease
• 237 SLC25A46 mutations cause a spectrum of disorders including CMT2 with optic atrophy (14 November, 2019)

  Carolynne Doherty, Menelaos Pipis, Andrea Cortese, Roy Poh, James Polke, Robert Pitceathly, Alexander Rossor, Mary Reilly
• 238 Usefulness of concomitant peripheral nerve and muscle biopsy (14 November, 2019)

  Rebecca Cooper, Eva Bunting, Zane Jaunmuktane, Ashirwad Merve, Alex Rosser, Matilde Laura, Hadi Manji, Mary M Reilly, Mike P Lunn, Aisling S Carr
• 240 A case of fulminant guillain-barré syndrome mimicking brain death (14 November, 2019)

  Jananee Sivagnanasundaram, Rebecca Broad, Lucy Tague, Catarina Quaresma, Richard Dittrich, Fadi Alkufri, Sreedharan Harikrishnan
• 246 Refractory seizures: a case of post-partum pyridoxine dependent epilepsy (14 November, 2019)

  Shreya Chaudhuri, Joanna Ball, Elaine Murphy, Kinan Muhammed
• 247 Autosomal recessive spinocerebellar ataxia type 10 (SCAR10); a rare diagnosis courtesy 100,000 genome project (14 November, 2019)

  Hassan W Zafar, Nicholas J Gutowski
• 248 A 57-year-old man with deteriorating mobility and deafness (14 November, 2019)

  Maria Stavrou, Jing Ming Yeo, Davenport Richard
• 250 AVXS-101 phase 3 study in spinal muscular atrophy type 1 (14 November, 2019)

  John W Day, Claudia A Chiriboga, Thomas O Crawford, Basil T Darras, Richard S Finkel, Anne M Connolly, Susan T Iannaccone, Nancy L Kuntz, Loren DM Peña, Meredith Schultz, Perry B Shieh, Edward C Smith, Imran Kausar, Douglas E Feltner, Francis G Ogrinc, Haojun Ouyang, Thomas A Macek, Elaine Kernbauer, Lynlee M Muehring, James L’Italien, Douglas M Sproule, Brian K Kaspar, Jerry R Mendell
• 251 Economic burden of spinal muscular atrophy type 1 (SMA1) (14 November, 2019)

  Omar Dabbous, Jennifer Seda, Imran Kausar, Marcus Droege, Douglas M Sproule
• 252 Speed to treatment effect in spinal muscular atrophy type 1 (14 November, 2019)

  Marcus Droege, Omar Dabbous, Douglas Feltner, Aaron Novack, Imran Kausar, Melissa Menier, Douglas Sproule
• 253 Idiopathic intracranial hypertension causing back pain and visual loss without headache (14 November, 2019)

  Sanjay Cheema, Sarah Cooper
• 254 Visual inversion illusion in a patient with multiple sclerosis (14 November, 2019)

  Sanjay Cheema, Mohammad Mahmud, Sarah Cooper
• 256 Thrombectomy in clinical practice, patient selection factors (14 November, 2019)

  Rose Stahl, Edward Littleton, Kurdow Nader
• 258 Can clinical experts agree on a diagnosis of TIA? (14 November, 2019)

  Seong Hoon Lee, Kah Long Aw, Ferghal McVerry, Mark McCarron
• 259 Use of internet connected cloud devices in stroke rehab-experience with a patient (14 November, 2019)

  K Dey, S Das
• 262 Consequence or coincidence? Migraine and stroke (14 November, 2019)

  Aung Oo
• 264 A rare cause of young stroke diagnosed by intracranial MR vessel wall imaging (14 November, 2019)

  Veena Aggarwal, Laura Benjamin, Robert Simister
• 265 Stroke-like symptoms on the coronary care unit: consider contrast induced encephalopathy (14 November, 2019)

  NLM Paul, T Hyde
• 267 Motor system biomarkers in amyotrophic lateral sclerosis (14 November, 2019)

  Evan C Edmond, Ricarda Menke, Malcolm Proudfoot, Kevin Talbot, Charlotte J Stagg, Martin R Turner
• 269 Prevention of hypertensive injury to the brain by intensive treatment in intracerebral haemorrhage (PROHIBIT-ICH): protocol for a randomised controlled trial of telemetric home BP monitoring (14 November, 2019)

  Iain McGurgan, Shahena Butt, Louise Silver, David Werring, Peter Rothwell
• 270 Queen square test of auditory cognition (QSTAC): diagnosing dementia with sound (14 November, 2019)

  Jeremy CS Johnson, Chris JD Hardy, Nttawan Utoomprukporn, Jonathan D Rohrer, Doris-Eva Bamiou, Jason D Warren
• 272 Inherited peripheral neuropathies: analysis of PDXK gene identifies a new treatable disorder (14 November, 2019)

  Viorica Chelban, Matthew Wilson, Natalia Zanetti, Eleni Zamba-Papanicolaou, Maria Conte, Carla Cordivari, Philippa Mills, Nicholas Wood, Peter Clayton, Henry Houlden
• 273 Risk of recurrent stroke in patients with intracranial stenosis: a population based study (14 November, 2019)

  Robert Hurford, Frank J Wolters, Linxin Li, Wilhelm Kuker, Peter M Rothwell
• 1 Asymptomatic meningiomas: not so indolent after all? (14 November, 2019)

  Edward Christopher
• 2 Meningitis management audit at a single centre: further support for culture-independent techniques in diagnosing meningitis (14 November, 2019)

  Simon Williams, Ghaniah Hassan-Smith